Pharmacoeconomic review report Tenofovir alafenamide (Vemlidy) (Gilead Sciences Canada, Inc.)
Tenofovir alafenamide (TAF, Vemlidy) is a prodrug of tenofovir, which is indicated for the treatment of chronic hepatitis B (HBV) in adults with compensated liver disease. The manufacturer submitted a price of 19.55 per 25 mg tablet, which, at the recommended dose of 25 mg daily, costs 19.55 per pat...
| Autor principal: | |
|---|---|
| Autor Corporativo: | |
| Formato: | Libro electrónico |
| Idioma: | Inglés |
| Publicado: |
Ottawa (ON) :
Canadian Agency for Drugs and Technologies in Health
2018.
|
| Colección: | Common drug review clinical review report.
|
| Materias: | |
| Ver en Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820267606719 |
